ZYRAYDI
Live / Allowed — Notice of allowance issued (as of 20 Jan 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 18 Mar 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97319656
- Mark type
- Stylized text
- Filed
- 18 Mar 2022
- Published for opposition
- 25 Nov 2025
- Attorney of record
- Elizabeth M. O'Donoghue
Goods and services
- Class 005 — Pharmaceuticals: Non-prescription medicines, namely, pills, tablets, capsules, caplets, and pharmaceutical preparations for the treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological, immune system related diseases and disorders, Parkinson's disease, insomnia, diabetic neuropathy, Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; medical and pharmaceutical preparations for the treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological, immune system related diseases and disorders, Parkinson's disease, insomnia, diabetic neuropathy, Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome
Owner
- Zelira Therapeutics Limited, Perth, AU
- Zelira Therapeutics Limited, Perth, AU
Prosecution history
- 20 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Nov 2025 — PUBLISHED FOR OPPOSITION
- 19 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 May 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 May 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 May 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 27 Feb 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 27 Feb 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 27 Feb 2024 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 27 Feb 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 27 Feb 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 27 Feb 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 01 Dec 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED